Drug Trial Radar · NCT06096259
Preventing Injured Knees From osteoArthritis: Severity Outcomes
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
512
Planned (sponsor's estimate)
Start
May 6, 2024
Primary completion
Dec 2029
Study completion Dec 2030
Sponsor
- Lead sponsor
- Brigham and Women's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Arthritis Foundation
- First posted
- Oct 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to find out if metformin is effective at reducing pain by delaying the onset of post-traumatic osteoarthritis (PTOA) after anterior cruciate ligament (ACL) reconstruction. This research study will compare metformin to placebo. The placebo tablet looks exactly like metformin, but contains no metformin. Placebos are used in research studies to see if the results are due to the study drug or due to other reasons. Metformin is approved by the U.S. Food and Drug Administration (FDA) to treat type II diabetes. Notably, it also has anti-inflammatory effects, suggesting it could benefit people who have an ACL injury and are undergoing ACL reconstruction.
Conditions
- Osteoarthritis, Knee
- Post-traumatic Osteoarthritis
- ACL Tear
Interventions
MetforminDrug
Metformin is an oral anti-hyperglycemic agent widely used as first-line treatment for type II diabetes to improve glycemic control. It is the fourth most commonly prescribed drug in the United States. Participants will receive commercially available extended-release metformin 500mg tablets manufactured by Granules India Limited, Hyderabad, India and then sourced, packaged, and labeled for the study by Sharp Labs. The study will follow standard dosing procedures for extended-release metformin. Participants will begin by taking 1x500 mg pill once a day, and then the dose will be increased in 500 mg/day increments every 5 days as tolerated, up to a maximum dose of 1500 mg daily.
PlaceboDrug
The study will use matching placebo tablets that are almost indistinguishable from the 500 mg metformin ER tablets. Participants will begin by taking 1x500 mg pill once a day, and then the dose will be increased in 500 mg/day increments every 5 days as tolerated, up to a maximum dose of 1500 mg daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- KOOS Pain ScoreTime frame: Average of 12 and 24 months
- Modified MOAKS Cartilage ScoreTime frame: 24 months
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Emory University
Atlanta, Georgia · Recruiting
University of Iowa Hospitals and Clinics
Iowa City, Iowa · Recruiting
University of Kentucky
Lexington, Kentucky · Recruiting
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Recruiting
Hospital for Special Surgery
New York, New York · Recruiting
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
The Ohio State University
Columbus, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.